- Home
- TROO vs SKYE Comparison
TROO vs SKYE Comparison
Compare TROO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- SKYE
- Stock Information
- Founded
- TROO 2005
- SKYE 2012
- Country
- TROO Hong Kong
- SKYE United States
- Employees
- TROO N/A
- SKYE N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- SKYE Health Care
- Exchange
- TROO Nasdaq
- SKYE Nasdaq
- Market Cap
- TROO N/A
- SKYE 73.4M
- IPO Year
- TROO N/A
- SKYE N/A
- Fundamental
- Price
- TROO $0.68
- SKYE $3.74
- Analyst Decision
- TROO
- SKYE Buy
- Analyst Count
- TROO 0
- SKYE 6
- Target Price
- TROO N/A
- SKYE $16.60
- AVG Volume (30 Days)
- TROO 52.4K
- SKYE 2.0M
- Earning Date
- TROO 07-07-2025
- SKYE 08-08-2025
- Dividend Yield
- TROO N/A
- SKYE N/A
- EPS Growth
- TROO N/A
- SKYE N/A
- EPS
- TROO N/A
- SKYE N/A
- Revenue
- TROO $10,073,000.00
- SKYE N/A
- Revenue This Year
- TROO N/A
- SKYE N/A
- Revenue Next Year
- TROO N/A
- SKYE N/A
- P/E Ratio
- TROO N/A
- SKYE N/A
- Revenue Growth
- TROO 182.24
- SKYE N/A
- 52 Week Low
- TROO $0.49
- SKYE $1.14
- 52 Week High
- TROO $4.89
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- TROO 43.70
- SKYE 66.59
- Support Level
- TROO $0.65
- SKYE $2.12
- Resistance Level
- TROO $0.71
- SKYE $5.75
- Average True Range (ATR)
- TROO 0.08
- SKYE 0.55
- MACD
- TROO -0.02
- SKYE 0.17
- Stochastic Oscillator
- TROO 8.39
- SKYE 45.82
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.